AZD1152(Barasertib)

製品コードS1051 バッチS105101

印刷

化学情報

Chemical Structure Synonyms N/A Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C26H31FN7O6P
分子量 587.54 CAS No. 722543-31-9
Solubility (25°C)* 体外 DMSO 100 mg/mL (170.2 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 AZD1152 is a selective inhibitor of Aurora B with Ki of 0.36 nM.
in vitro AZD1152 (Barasertib) is a pro-drug converting to active substance AZD1152-HQPA in human plasma, which inhibits Aurora-A, Aurora B-INCENP, and Aurora C-INCENP with Kis of 687 nM, 0.36 nM, and 17.0 nM, indicating a 100-fold selectivity for Aurora-B over Aurora-A. [1] This compound results in a dose-dependent inhibition of histone H3 phosphorylation on Ser10 in SW620 colorectal tumor cell line. [2] It also induces growth arrest of a variety of types of leukemia cells, with IC50 of 5, 12, and 8 nM for ALL PALL-2, MOLM13, MV4-11 respectively. [3]
in vivo AZD1152 (Barasertib) significantly suppresses PhH3 by 69% in SW620 colon tumors at 2.5 mg/kg/d. It also inhibits growth in a panel of human tumor xenografts including Colo205, A549, and HL-60 at 10–150 mg/kg/d, with inhibition rates ranging from 55% to 100%. Additional results show that cells exposed to this compound end up in apoptosis.[2] At 25 mg/kg, it markedly suppresses the growth and weights of treated tumors in MOLM13 xenografts.[3]
特徴 Selectivity for Aurora-B over Aurora-A.

プロトコル(参考用のみ)

キナーゼアッセイ Affinity determination
AZD1152(Barasertib) are incubated with Aurora A or Aurora B-INCENP and the substrate peptide. Twenty microliters of reaction mix (25 mM Tris-HCl, 12.7 mM KCl, 2.5 mM NaF, 0.6 mM dithiothreitol, 6.25 mM MnCl2, 7.5μM ATP for Aurora A assay and 15 μM for Aurora B-INCENP assay, 6.25 μM peptide substrate containing 0.2 μCi [γ33P]ATP) is then added to all test wells to start the reaction (to give a final volume of 50 μL). Plates are incubated at room temperature for 60 min, reactions are stopped by addition of 100 μL of 20% v/v orthophosphoric acid, and peptide substrate is captured on positively charged nitrocellulose P30 filtermat using a 96-well plate harvester and then assayed for incorporation of 33P with a Beta plate counter.
細胞アッセイ 細胞株 ALL PALL-2; MOLM13; MV4-11 cells
濃度 ~100 nM
反応時間 48 h
実験の流れ Leukemic cells are grown in liquid culture for 2 days in the presence of various concentrations of AZD1152-HQPA (1-100 nM), a derivative of AZD1152 (Barasertib). Growth inhibition is measured by thymidine uptake; the percent inhibition is graphed and the concentration of this compound that induced 50% growth inhibition (IC50) of leukemia cells is determined.
動物実験 動物モデル Male nude mice bearing SW620, Colo205, A549, and HL-60 human tumor xenografts.
投薬量 2.5-150 mg/kg
投与方法 i.v. i.p. s.c.

参考

  • http://www.aacr.org/home/scientists/meetings--workshops/molecular-targets-and-cancer-therapeutics/previous-molecular-targets-and-cancer-therapeutics-conferences/2005-molecular-targets-and-cancer-therapeutics/proceedings.aspx
  • http://www.ncbi.nlm.nih.gov/pubmed?term=17575233
  • http://www.ncbi.nlm.nih.gov/pubmed?term=17495131
  • http://www.ncbi.nlm.nih.gov/pubmed?term=17373783

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Rsk2 and Lrp5 deficiency limit osteosarcoma growth in cFos-transgenic mice by different mechanisms [ ProQuest , 2023, 30683696] PubMed: None
Vitamins C and K3: A Powerful Redox System for Sensitizing Leukemia Lymphocytes to Everolimus and Barasertib [Ivanova D, et al. Anticancer Res, 2018, 38(3):1407-1414] PubMed: 29491065
Aurora Kinases as Druggable Targets in Pediatric Leukemia: Heterogeneity in Target Modulation Activities and Cytotoxicity by Diverse Novel Therapeutic Agents [Jayanthan A, et al. PLoS One, 2014, 9(7):e102741] PubMed: 25048812
Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death. [Ratushny V, et al. Oncogene, 2012, 31(10):1217-27] PubMed: 21785464
Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells. [Bonet C, et al. J Biol Chem, 2012, 287(35):29887-98] PubMed: 22767597
Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families [Glaser KB, et al. J Pharmacol Exp Ther, 2012, 343(3):617-27] PubMed: 22935731
Preclinical Characterization of ABT-348, a Kinase Inhibitor Targeting the Aurora, Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor … [Glaser KB, et al. J Pharmacol Exp Ther, 2012, 343(3):617-27] PubMed: 22935731
Aurora A and Aurora B jointly coordinate chromosome segregation and anaphase microtubule dynamics. [H間arat N, et al. J Cell Biol, 2011, 195(7):1103-13] PubMed: 22184196

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。